0

Pharmacological Targeting of GLI1 Inhibits Proliferation, Tumor Emboli Formation and in Vivo Tumor Growth of Inflammatory Breast Cancer Cells

Helen O Oladapo, Michael Tarpley, Scott J Sauer, Kezia A Addo, Shalonda M Ingram, Dillon Strepay, Ben K Ehe, Lhoucine Chdid, Michael Trinkler, Jose R Roques, David B Darr, Jodie M Fleming, Gayathri R Devi, etc.

Cancer Lett. 2017 Dec 28;411:136-149.

PMID: 28965853

Abstract:

Activation of the Hedgehog (Hh) pathway effector GLI1 is linked to tumorigenesis and invasiveness in a number of cancers, with targeting of GLI1 by small molecule antagonists shown to be effective. We profiled a collection of GLI antagonists possessing distinct mechanisms of action for efficacy in phenotypic models of inflammatory and non-inflammatory breast cancer (IBC and non-IBC) that we showed expressed varying levels of Hh pathway mediators. Compounds GANT61, HPI-1, and JK184 decreased cell proliferation, inhibited GLI1 mRNA expression and decreased the number of colonies formed in TN-IBC (SUM149) and TNBC (MDA-MB-231 and SUM159) cell lines. In addition, GANT61 and JK184 significantly down-regulated GLI1 targets that regulate cell cycle (cyclin D and E) and apoptosis (Bcl2). GANT61 reduced SUM149 spheroid growth and emboli formation, and in orthotopic SUM149 tumor models significantly decreased tumor growth. We successfully utilized phenotypic profiling to identify a subset of GLI1 antagonists that were prioritized for testing in in vivo models. Our results indicated that GLI1 activation in TN-IBC as in TNBC, plays a vital role in promoting cell proliferation, motility, tumor growth, and formation of tumor emboli.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
AP315703527 JK184 JK184 315703-52-7 Price
qrcode